HYLORIS PHARMACEUTIC

HYL
Real-time Quote. Real-time  - 05/26 11:35:07 am
14.94EUR -0.27%

Hyloris Announces Approval of Maxigesic® IV in the UK and Ireland

10/19/2021 | 01:00am
Hyloris Pharmaceuticals SA announces further extension of the European footprint of Maxigesic® IV, a novel, unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, for the treatment of post-operative pain. Maxigesic IV has now obtained regulatory approvals in the UK and Ireland, thereby increasing the number of countries in which Hyloris’ partner AFT Pharmaceuticals obtained regulatory approval for Maxigesic IV to 27 countries, from 21 countries at the end of March 2021. Kensington Pharmaceuticals Ltd., the distributor for the UK, and Jed Pharma Ltd, the distributor in Ireland, are now gearing up to commence sales in the first quarter of 2022.
© S&P Capital IQ 2022
Copier lien
All news about HYLORIS PHARMACEUTICALS SA
04/01
03/31
03/31
03/16
03/16